{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:48:33Z","timestamp":1790077713190,"version":"4.0.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T00:00:00Z","timestamp":1573084800000},"content-version":"vor","delay-in-days":1590,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1093\/annonc\/mdv172","type":"journal-article","created":{"date-parts":[[2015,4,8]],"date-time":"2015-04-08T04:06:21Z","timestamp":1428465981000},"page":"1500-1504","source":"Crossref","is-referenced-by-count":30,"title":["Variation in transplacental transfer of tyrosine kinase inhibitors in the human perfused cotyledon model"],"prefix":"10.1016","volume":"26","author":[{"given":"C.","family":"Jovelet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Seck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Simasotchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Broutin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Goffinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Bidart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Paci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1093\/annonc\/mdv172_bb0010","first-page":"1","article-title":"Death in the United States, 2007","author":"Mini\u00f1o","year":"2009","journal-title":"NCHS Data Brief"},{"issue":"Suppl 5","key":"10.1093\/annonc\/mdv172_bb0015","doi-asserted-by":"crossref","first-page":"v266","DOI":"10.1093\/annonc\/mdq198","article-title":"Cancer, fertility and pregnancy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Pentheroudakis","year":"2010","journal-title":"Ann Oncol"},{"issue":"9815","key":"10.1093\/annonc\/mdv172_bb0020","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/S0140-6736(11)61092-1","article-title":"Breast cancer in pregnancy","volume":"379","author":"Amant","year":"2012","journal-title":"Lancet"},{"issue":"7","key":"10.1093\/annonc\/mdv172_bb0025","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1200\/JCO.2005.04.6557","article-title":"Pregnancy among patients with chronic myeloid leukemia treated with imatinib","volume":"24","author":"Ault","year":"2006","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1093\/annonc\/mdv172_bb0030","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1182\/blood-2007-10-114900","article-title":"The effects of imatinib on pregnancy outcome","volume":"111","author":"Pye","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1093\/annonc\/mdv172_bb0035","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11845-014-1084-5","article-title":"Pregnancy outcome in chronic myeloid leukemia patients on imatinib therapy","volume":"184","author":"Mukhopadhyay","year":"2015","journal-title":"Ir J Med Sci"},{"issue":"9","key":"10.1093\/annonc\/mdv172_bb0040","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.3109\/10428194.2013.866662","article-title":"Pregnancy outcomes in patients with chronic myeloid leukemia treated with imatinib mesylate: short report from a developing country","volume":"55","author":"Iqbal","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"25","key":"10.1093\/annonc\/mdv172_bb0045","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1093\/annonc\/mdv172_bb0050","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.lungcan.2011.08.008","article-title":"Successful pregnancy with epidermal growth factor receptor tyrosine kinase inhibitor treatment of metastatic lung adenocarcinoma presenting with respiratory failure","volume":"74","author":"Lee","year":"2011","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1093\/annonc\/mdv172_bb0055","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.lungcan.2007.10.025","article-title":"Erlotinib administration for advanced non-small cell lung cancer during the first 2 months of unrecognized pregnancy","volume":"60","author":"Zambelli","year":"2008","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1093\/annonc\/mdv172_bb0060","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.lungcan.2012.03.026","article-title":"Use of erlotinib throughout pregnancy: a case-report of a patient with metastatic lung adenocarcinoma","volume":"77","author":"Rivas","year":"2012","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1093\/annonc\/mdv172_bb0065","doi-asserted-by":"crossref","first-page":"514.e1","DOI":"10.1016\/j.ajog.2012.10.007","article-title":"Comparative transplacental transfer of taxanes using the human perfused cotyledon placental model","volume":"207","author":"Berveiller","year":"2012","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"10.1093\/annonc\/mdv172_bb0070","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/annonc\/mdg250","article-title":"Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (\u2018Iressa\u2019, ZD1839) in Japanese patients with solid malignant tumors","volume":"14","author":"Nakagawa","year":"2003","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdv172_bb0075","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1093\/annonc\/mdv172_bb0080","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1158\/1078-0432.CCR-07-0437","article-title":"A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies","volume":"14","author":"Chiorean","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv172_bb0085","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000410667","article-title":"Criteria for evaluating perfusion experiments and presentation of results","volume":"13","author":"Challier","year":"1985","journal-title":"Contrib Gynecol Obstet"},{"issue":"3","key":"10.1093\/annonc\/mdv172_bb0090","first-page":"e533","article-title":"Prediction of placental drug transfer using the human placental perfusion model","volume":"18","author":"Hutson","year":"2011","journal-title":"J Popul Ther Clin Pharmacol"},{"issue":"2","key":"10.1093\/annonc\/mdv172_bb0095","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.critrevonc.2013.08.003","article-title":"Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects","volume":"89","author":"Bronte","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1093\/annonc\/mdv172_bb0100","first-page":"3","article-title":"Placental transfer of drugs","volume":"69","author":"Evain-Brion","year":"2014","journal-title":"Th\u00e9rapie"},{"issue":"suppl 3","key":"10.1093\/annonc\/mdv172_bb0105","doi-asserted-by":"crossref","first-page":"iii27","DOI":"10.1093\/annonc\/mdu199","article-title":"Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Reck","year":"2014","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdv172_bb0110","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/annonc\/mdp517","article-title":"Taxanes for breast cancer during pregnancy: a systematic review","volume":"21","author":"Mir","year":"2010","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1093\/annonc\/mdv172_bb0115","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1093\/annonc\/mdu140","article-title":"Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel","volume":"25","author":"van Hasselt","year":"2014","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1093\/annonc\/mdv172_bb0120","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1093\/annonc\/mdu376","article-title":"Drug selection and dosing in pregnant cancer patients: insights from clinical pharmacokinetics","volume":"25","author":"Berveiller","year":"2014","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdv172_bb0125","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/IGC.0000000000000062","article-title":"Gynecologic cancers in pregnancy: guidelines of a second international consensus meeting","volume":"24","author":"Amant","year":"2014","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1093\/annonc\/mdv172_bb0130","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.lungcan.2014.06.003","article-title":"Efficacy and safety of gefitinib during pregnancy: case report and literature review","volume":"85","author":"Gil","year":"2014","journal-title":"Lung Cancer"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419344977?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419344977?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/26\/7\/1500\/16702758\/mdv172.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:53:50Z","timestamp":1624521230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419344977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0923753419344977"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdv172","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]}}}